Literature DB >> 2143498

Myelopoiesis-associated suppressor-cell activity in mice with Lewis lung carcinoma tumors: interferon-gamma plus tumor necrosis factor-alpha synergistically reduce suppressor cell activity.

M R Young1, M E Young, M A Wright.   

Abstract

The myelopoietic stimulation which occurs in mice bearing metastatic Lewis lung carcinoma (LLC-C3) tumors is accompanied by immune suppression and the appearance of myelopoiesis-associated immune suppressor cells in the bone marrow and spleen. Low doses of recombinant murine interferon-gamma (IFN-gamma) plus recombinant human tumor necrosis factor-alpha (TNF-alpha) were used to limit myelopoiesis and, in turn, reduce the presence of myelopoiesis-associated immune suppressor cells in LLC-C3 tumor bearers. Neither IFN-gamma nor TNF-alpha alone had any effect in vitro on the growth of myeloid progenitor cells into colonies or on the suppressive activity of bone-marrow cells from LLC-C3-bearing mice. However, the combination of low doses of IFN-gamma and TNF-alpha synergistically inhibited both the growth of myeloid progenitor cells into colonies and the suppressive activity of bone-marrow cells from tumor-bearers. Similar results were obtained in vivo. When used alone, neither IFN-gamma nor TNF-alpha had any effect on myelopoiesis or on suppressor-cell activity. When combined, IFN-gamma plus TNF-alpha synergistically suppressed myelopoiesis and the presence of immune suppressive cells both in the bone marrow and in the spleen of tumor bearers. T-lymphocyte blastogenic and NK cytotoxic activities of the tumor-bearers were restored only after treatment with both IFN-gamma and TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143498     DOI: 10.1002/ijc.2910460217

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta.

Authors:  M R Young; M A Wright; M Coogan; M E Young; J Bagash
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 2.  Advancements in immune tolerance.

Authors:  Ping-Ying Pan; Junko Ozao; Zuping Zhou; Shu-Hsia Chen
Journal:  Adv Drug Deliv Rev       Date:  2007-10-05       Impact factor: 15.470

3.  Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients.

Authors:  Anamika Bose; Tathagata Chakraborty; Krishnendu Chakraborty; Smarajit Pal; Rathindranath Baral
Journal:  Cancer Immun       Date:  2008-06-12

Review 4.  Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.

Authors:  Anca Dorhoi; Leigh A Kotzé; Jay A Berzofsky; Yongjun Sui; Dmitry I Gabrilovich; Ankita Garg; Richard Hafner; Shabaana A Khader; Ulrich E Schaible; Stefan He Kaufmann; Gerhard Walzl; Manfred B Lutz; Robert N Mahon; Suzanne Ostrand-Rosenberg; William Bishai; Nelita du Plessis
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

5.  Tolerance and immune suppression in the tumor microenvironment.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Cell Immunol       Date:  2015-09-30       Impact factor: 4.868

6.  Increasing infiltration and activation of CD8+ tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte/macrophage progenitor cells with low doses of interferon gamma plus tumor necrosis factor alpha.

Authors:  M R Young; G McCloskey; M A Wright; A S Pak
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

7.  Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence.

Authors:  M R Young; J Ihm; Y Lozano; M A Wright; M M Prechel
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

8.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Authors:  Junko Ozao-Choy; Ge Ma; Johnny Kao; George X Wang; Marcia Meseck; Max Sung; Myron Schwartz; Celia M Divino; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

Review 9.  History of myeloid-derived suppressor cells.

Authors:  James E Talmadge; Dmitry I Gabrilovich
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

10.  Tumor infiltration by myeloid suppressor cells in response to T cell activation in rat gliomas.

Authors:  Martin R Graf; Jeremy T Sauer; Randall E Merchant
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.